In this study, we demonstrate that the OLIG2 inhibitor CT-179 can target OLIG2-expressing tumor stem cells that are resistant to conventional therapies, and thus increase the efficacy of multi-modal therapy, most prominently in SHH-driven MB. This evidence concerns the gene OLIG2 and neoplasm.